Poon A. Christine's most recent trade in Regeneron Pharmaceuticals, Inc. was a trade of 1,962 Non-Qualified Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regeneron Pharma | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 1,962 | 1,962 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 155 | 5,219 (0%) | 0% | 0 | Common Stock | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2025 | 151 | 13,299 | - | - | Notional Shares - Mandatory | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2025 | 46 | 4,082 | - | - | Notional Shares - Optional | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2025 | 19 | 1,738 | - | - | 2025 Restricted Stock Units | |
| Regeneron Pharma | Christine A. Poon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 520.01 per share. | 29 Oct 2025 | 6,500 | 8,852 (0%) | 0% | 520.0 | 3,380,065 | Common Stock |
| Regeneron Pharma | Christine A. Poon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Oct 2025 | 6,500 | 2,712 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Christine A. Poon | Director | Sale of securities on an exchange or to another person at price $ 653.50 per share. | 29 Oct 2025 | 2,735 | 5,467 (0%) | 0% | 653.5 | 1,787,323 | Common Stock |
| Regeneron Pharma | Christine A. Poon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Oct 2025 | 2,712 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Christine A. Poon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 520.01 per share. | 29 Oct 2025 | 2,712 | 5,064 (0%) | 0% | 520.0 | 1,410,267 | Common Stock |
| Regeneron Pharma | Christine A. Poon | Director | Sale of securities on an exchange or to another person at price $ 654.42 per share. | 29 Oct 2025 | 1,915 | 3,552 (0%) | 0% | 654.4 | 1,253,214 | Common Stock |
| Regeneron Pharma | Christine A. Poon | Director | Sale of securities on an exchange or to another person at price $ 656.50 per share. | 29 Oct 2025 | 712 | 2,740 (0%) | 0% | 656.5 | 467,428 | Common Stock |
| Regeneron Pharma | Christine A. Poon | Director | Sale of securities on an exchange or to another person at price $ 652.68 per share. | 29 Oct 2025 | 650 | 8,202 (0%) | 0% | 652.7 | 424,242 | Common Stock |
| Regeneron Pharma | Christine A. Poon | Director | Sale of securities on an exchange or to another person at price $ 657.29 per share. | 29 Oct 2025 | 388 | 2,352 (0%) | 0% | 657.3 | 255,029 | Common Stock |
| Regeneron Pharma | Christine A. Poon | Director | Sale of securities on an exchange or to another person at price $ 655.10 per share. | 29 Oct 2025 | 100 | 3,452 (0%) | 0% | 655.1 | 65,510 | Common Stock |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Sep 2025 | 163 | 13,148 | - | - | Notional Shares - Mandatory | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Sep 2025 | 50 | 4,035 | - | - | Notional Shares - Optional | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Sep 2025 | 21 | 1,718 | - | - | 2025 Restricted Stock Units | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 164 | 12,984 | - | - | Notional Shares - Mandatory | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 50 | 3,985 | - | - | Notional Shares - Optional | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 21 | 1,697 | - | - | 2025 Restricted Stock Units | |
| Neurocrine Biosciences Inc | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 3,318 | 3,318 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Christine A. Poon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 1,435 | 0 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Christine A. Poon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 1,435 | 1,435 (0%) | 0% | 0 | Common Stock | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2025 | 1,675 | 1,675 | - | - | 2025 Restricted Stock Units | |
| Prudential Financial | Christine A. Poon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2025 | 1,321 | 12,904 (0%) | 0% | 0 | Common Stock | |
| Prudential Financial | Christine A. Poon | Director | Sale or transfer of securities back to the company at price $ 107.40 per share. | 13 May 2025 | 1,321 | 11,583 (0%) | 0% | 107.4 | 141,875 | Common Stock |
| Prudential Financial | Christine A. Poon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2025 | 1,321 | 0 | - | - | 2024 Restricted Stock Units | |
| Sherwin-Williams | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 347.50 per share. | 04 Apr 2025 | 4 | 2,573 (0%) | 0% | 347.5 | 1,390 | Common Stock |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 162 | 12,819 | - | - | Notional Shares - Mandatory | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 49 | 3,934 | - | - | Notional Shares - Optional | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 16 | 1,321 | - | - | 2024 Restricted Stock Units | |
| Sherwin-Williams | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 517 | 12,386 (0%) | 0% | 0 | Common Stock | |
| Sherwin-Williams | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 337.56 per share. | 03 Jan 2025 | 25 | 2,563 (0%) | 0% | 337.6 | 8,439 | Common Stock |
| Regeneron Pharma | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 1,958 | 1,958 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 166 | 2,352 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | Christine A. Poon | Director | 02 Jan 2025 | 14 | 2,186 (0%) | 0% | 0 | Common Stock | ||
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2024 | 134 | 12,656 | - | - | Notional Shares - Mandatory | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2024 | 41 | 3,884 | - | - | Notional Shares - Optional | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2024 | 13 | 1,304 | - | - | 2024 Restricted Stock Units | |
| Sherwin-Williams | Christine A. Poon | Director | 04 Oct 2024 | 22 | 2,533 (0%) | 0% | 383.5 | 8,436 | Common Stock | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2024 | 138 | 12,521 | - | - | Notional Shares - Mandatory | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2024 | 42 | 3,843 | - | - | Notional Shares - Optional | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2024 | 14 | 1,290 | - | - | 2024 Restricted Stock Units | |
| Regeneron Pharma | Christine A. Poon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 413.33 per share. | 15 Aug 2024 | 10,838 | 13,010 (0%) | 0% | 413.3 | 4,479,671 | Common Stock |
| Regeneron Pharma | Christine A. Poon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2024 | 10,838 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Christine A. Poon | Director | Sale of securities on an exchange or to another person at price $ 1159.56 per share. | 15 Aug 2024 | 5,352 | 2,506 (0%) | 0% | 1159.6 | 6,205,965 | Common Stock |
| Regeneron Pharma | Christine A. Poon | Director | Sale of securities on an exchange or to another person at price $ 1156.30 per share. | 15 Aug 2024 | 2,368 | 9,630 (0%) | 0% | 1156.3 | 2,738,118 | Common Stock |
| Regeneron Pharma | Christine A. Poon | Director | Sale of securities on an exchange or to another person at price $ 1157.33 per share. | 15 Aug 2024 | 1,560 | 8,070 (0%) | 0% | 1157.3 | 1,805,435 | Common Stock |
| Regeneron Pharma | Christine A. Poon | Director | Sale of securities on an exchange or to another person at price $ 1155.72 per share. | 15 Aug 2024 | 1,012 | 11,998 (0%) | 0% | 1155.7 | 1,169,589 | Common Stock |
| Regeneron Pharma | Christine A. Poon | Director | Sale of securities on an exchange or to another person at price $ 1160.45 per share. | 15 Aug 2024 | 234 | 2,272 (0%) | 0% | 1160.4 | 271,545 | Common Stock |
| Regeneron Pharma | Christine A. Poon | Director | Sale of securities on an exchange or to another person at price $ 1158.02 per share. | 15 Aug 2024 | 212 | 7,858 (0%) | 0% | 1158.0 | 245,500 | Common Stock |
| Regeneron Pharma | Christine A. Poon | Director | Sale of securities on an exchange or to another person at price $ 1161.32 per share. | 15 Aug 2024 | 100 | 2,172 (0%) | 0% | 1161.3 | 116,132 | Common Stock |
| Sherwin-Williams | Christine A. Poon | Director | 05 Jul 2024 | 28 | 2,505 (0%) | 0% | 301.3 | 8,437 | Common Stock | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 139 | 12,382 | - | - | Notional Shares - Mandatory | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 42 | 3,800 | - | - | Notional Shares - Optional | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 14 | 1,276 | - | - | 2024 Restricted Stock Units | |
| Neurocrine Biosciences Inc | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 2,982 | 2,982 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences Inc | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 1,435 | 1,435 | - | - | Restricted Stock Unit | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2024 | 1,261 | 1,261 | - | - | 2024 Restricted Stock Units | |
| Prudential Financial | Christine A. Poon | Director | Sale or transfer of securities back to the company at price $ 117.95 per share. | 09 May 2024 | 1,935 | 11,583 (0%) | 0% | 117.9 | 228,233 | Common Stock |
| Prudential Financial | Christine A. Poon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 May 2024 | 1,935 | 0 | - | - | 2023 Restricted Stock Units | |
| Prudential Financial | Christine A. Poon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 May 2024 | 1,935 | 13,518 (0%) | 0% | 0 | Common Stock | |
| Sherwin-Williams | Christine A. Poon | Director | 05 Apr 2024 | 25 | 2,471 (0%) | 0% | 337.5 | 8,438 | Common Stock | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 140 | 12,243 | - | - | Notional Shares - Mandatory | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 43 | 3,757 | - | - | Notional Shares - Optional | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 22 | 1,935 | - | - | 2023 Restricted Stock Units | |
| Sherwin-Williams | A. Christine Poon | Director | 13 Feb 2024 | 594 | 11,869 (0%) | 0% | 0 | Common Stock | ||
| Sherwin-Williams | A. Christine Poon | Director | 05 Jan 2024 | 28 | 2,440 (0%) | 0% | 301.3 | 8,437 | Common Stock | |
| Regeneron Pharma | Poon A. Christine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 1,607 | 1,607 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 135 | 2,172 (0%) | 0% | 0 | Common Stock | |
| Prudential Financial | A. Christine Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2023 | 142 | 12,102 | - | - | Notional Shares - Mandatory | |
| Prudential Financial | Christine Poon A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2023 | 43 | 3,714 | - | - | Notional Shares - Optional | |
| Prudential Financial | A. Christine Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2023 | 22 | 1,913 | - | - | 2023 Restricted Stock Units | |
| Sherwin-Williams | Christine A. Poon | Director | 06 Oct 2023 | 32 | 2,407 (0%) | 0% | 253.9 | 8,126 | Common Stock | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Sep 2023 | 148 | 11,960 | - | - | Notional Shares - Mandatory | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Sep 2023 | 45 | 3,671 | - | - | Notional Shares - Optional | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Sep 2023 | 23 | 1,890 | - | - | 2023 Restricted Stock Units | |
| Regeneron Pharma | Christine A. Poon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2023 | 12,280 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Christine A. Poon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 273.67 per share. | 23 Aug 2023 | 12,280 | 14,317 (0%) | 0% | 273.7 | 3,360,668 | Common Stock |
| Regeneron Pharma | Christine A. Poon | Director | Sale of securities on an exchange or to another person at price $ 840.65 per share. | 23 Aug 2023 | 6,450 | 2,537 (0%) | 0% | 840.7 | 5,422,193 | Common Stock |
| Regeneron Pharma | Christine A. Poon | Director | Sale of securities on an exchange or to another person at price $ 839.45 per share. | 23 Aug 2023 | 3,032 | 8,987 (0%) | 0% | 839.4 | 2,545,212 | Common Stock |
| Regeneron Pharma | Christine A. Poon | Director | Sale of securities on an exchange or to another person at price $ 838.60 per share. | 23 Aug 2023 | 1,998 | 12,019 (0%) | 0% | 838.6 | 1,675,523 | Common Stock |
| Regeneron Pharma | Christine A. Poon | Director | Sale of securities on an exchange or to another person at price $ 841.05 per share. | 23 Aug 2023 | 500 | 2,037 (0%) | 0% | 841.1 | 420,525 | Common Stock |
| Regeneron Pharma | Christine A. Poon | Director | Sale of securities on an exchange or to another person at price $ 837.92 per share. | 23 Aug 2023 | 300 | 14,017 (0%) | 0% | 837.9 | 251,376 | Common Stock |
| Neurocrine Biosciences Inc | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2023 | 16,375 | 16,375 | - | - | Non-Qualified Stock Option | |
| Sherwin-Williams | Christine A. Poon | Director | 07 Jul 2023 | 31 | 2,370 (0%) | 0% | 262.1 | 8,126 | Common Stock | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 167 | 11,811 | - | - | Notional Shares - Mandatory | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 51 | 3,625 | - | - | Notional Shares - Optional | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 26 | 1,867 | - | - | 2023 Restricted Stock Units | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2023 | 1,840 | 1,840 | - | - | 2023 Restricted Stock Units | |
| Prudential Financial | Christine A. Poon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 May 2023 | 1,517 | 13,100 (0%) | 0% | 0 | Common Stock | |
| Prudential Financial | Christine A. Poon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 May 2023 | 1,517 | 0 | - | - | 2022 Restricted Stock Units | |
| Prudential Financial | Christine A. Poon | Director | Sale or transfer of securities back to the company at price $ 81.50 per share. | 09 May 2023 | 1,517 | 11,583 (0%) | 0% | 81.5 | 123,636 | Common Stock |
| Sherwin-Williams | Christine A. Poon | Director | 10 Apr 2023 | 36 | 2,332 (0%) | 0% | 225.7 | 8,124 | Common Stock | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 174 | 11,643 | - | - | Notional Shares - Mandatory | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 53 | 3,573 | - | - | Notional Shares - Optional | |
| Prudential Financial | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 22 | 1,517 | - | - | 2022 Restricted Stock Units | |
| Sherwin-Williams | Christine A. Poon | Director | 14 Feb 2023 | 711 | 11,275 (0%) | 0% | 0 | Common Stock | ||
| Sherwin-Williams | Christine A. Poon | Director | 06 Jan 2023 | 34 | 2,289 (0%) | 0% | 238.9 | 8,124 | Common Stock | |
| Regeneron Pharma | Christine A. Poon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 1,929 | 1,929 | - | - | Non-Qualified Stock Option (right to buy) |